# HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen

> **NCT02776202** · PHASE2 · UNKNOWN · sponsor: **National Guard Health Affairs** · enrollment: 15 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Fludarabine monophosphate

## Key facts

- **NCT ID:** NCT02776202
- **Lead sponsor:** National Guard Health Affairs
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02776202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02776202, "HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02776202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*